公司积极承担包括国家"863"计划等在内的国家、省、市各类科研及技术攻关项目共40余项，多个重大 课题成功通过验收，荣获深圳市科技创新奖、国家级专精特新"小巨人"企业等荣誉，不仅填补了深圳市 血液制品行业的空白，更助力深圳市生物医药产业的蓬勃发展。2022年公司与白俄罗斯有关政府机构达 成生产许可及技术转移服务相关合作协议，成为国内首个实现血液制品技术输出的企业。 从深圳市卫武光明生物制品厂的技术员起步，2025年是我在卫光生物（002880）的第31年。30多年来， 我始终奋斗在血液制品生产科研一线，见证并引领着卫光生物从最初的一家地方小厂，历经改制、更 名、敲钟上市，成为国内研发实力雄厚的血液制品领先企业。 我始终坚信，血液制品行业是守护生命健康的朝阳产业，而创新则是这个产业的核心生命力。如今的卫 光生物，已构建起涵盖人血白蛋白、静注人免疫球蛋白、凝血因子三大类11个品种23个规格的产品体 系，血浆综合利用率和产品品种数量均位于国内血液制品行业前列。 站在"十五五"开局的历史节点，卫光生物也正牢牢抓住光明区建设综合性国家科学中心先行启动区这一 历史性发展机遇，与光明科学城建设同频共振。未来，卫光生物将围绕 ...

Core Viewpoint - The company, Shenzhen Weiguang Biological Products Co., Ltd., is engaged in the research, production, and sales of blood products, which are crucial for medical emergencies and are considered strategic reserves by the state. The company has proposed a cash dividend distribution plan based on its financial performance in 2024. Company Overview - The company specializes in blood products, including albumin, immunoglobulin, and coagulation factors, which are derived from healthy human blood or plasma. These products play an irreplaceable role in medical emergencies, wars, and major disasters [3][4]. Industry Development - The blood products industry in China has seen significant growth since its introduction in the 1960s, with fewer than 30 companies currently operating. Major international players hold over 80% of the global market share [4][5]. - The industry has high entry barriers and strict regulatory oversight, with no new production companies approved since 2001. The government has implemented comprehensive regulations covering all aspects of blood product production [5][6]. Market Potential - The global blood products market is expected to grow due to increasing patient numbers and the rising usage rates of immunoglobulin and albumin. In China, the per capita demand for blood products is anticipated to increase significantly, with a large space for domestic production to replace imports [6][7]. - In 2024, China's plasma collection is projected to reach approximately 13,400 tons, indicating substantial growth potential compared to developed countries [6][7]. Future Industry Trends - Domestic demand for blood products is expected to rise, driven by an aging population and increased medical needs. The number of plasma collection stations is likely to increase, enhancing supply capabilities [6][7]. - Companies are focusing on technological research and development to improve the utilization rate of plasma and expand product offerings [7][8]. Company Position - The company is one of the earliest blood product manufacturers in China and has a strong operational management capability with nine plasma collection stations. It ranks among the top in plasma collection volume within the industry [10][11]. - The company has established a cooperative agreement with Belarus for the production and technology transfer of blood products, marking it as the first in China to achieve technology export in this field [11]. Financial Data - In 2024, the company reported a net profit of approximately 253.52 million yuan, with a proposed cash dividend of 2 yuan per 10 shares, totaling 45.36 million yuan [60][62].